File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Retinal blood flow in response to an intravitreal injection of ranibizumab for neovascular age-related macular degeneration

TitleRetinal blood flow in response to an intravitreal injection of ranibizumab for neovascular age-related macular degeneration
Authors
Keywordsage-related macular degeneration
Issue Date2012
Citation
Acta Ophthalmologica, 2012, v. 90, n. 1 How to Cite?
AbstractPurpose: To assess the hemodynamic response of retinal arterioles and venules following a single intravitreal injection of ranibizumab in neovascular age-related macular degeneration (NV-AMD) patients and to assess the influence of the number of prior injections on this response. Methods: Fifteen NV-AMD patients were prospectively recruited and grouped according to the dosage of ranibizumab previously received. Group 1 NV-AMD patients (n = 7) had previously received 1.50 mg or less, and group 2 patients (n = 8) had received more than 1.50 mg in the study eye. A group of 12 non-NV AMD patients were also recruited for control comparison. Vessel diameter, centreline blood velocity and blood flow were assessed with the Canon Laser Blood Flowmeter immediately prior to an injection and at a mean follow-up of 37.7 and 36.7 days for group 1 and group 2 patients, respectively. Results: The NV-AMD patients as a whole and the group 1 cohort had a significantly greater arteriolar diameter at baseline than the non-NV AMD patients. There was a significant reduction in arteriolar diameter, velocity and blood flow in group 1 but not in group 2 NV-AMD patients at follow-up. There was only an insignificant decrease in measured parameters of the retinal venules. At follow-up, there was no difference in the diameter, velocity or flow between AMD patients. Conclusion: Intravitreal ranibizumab treatment for NV-AMD induces a reduction in arteriolar diameter, velocity, and blood flow in patients who have received <1.50 mg of ranibizumab. © 2011 Acta Ophthalmologica Scandinavica Foundation.
Persistent Identifierhttp://hdl.handle.net/10722/228129
ISSN
2015 Impact Factor: 3.032
2015 SCImago Journal Rankings: 1.473

 

DC FieldValueLanguage
dc.contributor.authorMicieli, Jonathan A.-
dc.contributor.authorTsui, Edmund-
dc.contributor.authorLam, Wai Ching-
dc.contributor.authorBrent, Michael H.-
dc.contributor.authorDevenyi, Robert G.-
dc.contributor.authorHudson, Chris-
dc.date.accessioned2016-08-01T06:45:15Z-
dc.date.available2016-08-01T06:45:15Z-
dc.date.issued2012-
dc.identifier.citationActa Ophthalmologica, 2012, v. 90, n. 1-
dc.identifier.issn1755-375X-
dc.identifier.urihttp://hdl.handle.net/10722/228129-
dc.description.abstractPurpose: To assess the hemodynamic response of retinal arterioles and venules following a single intravitreal injection of ranibizumab in neovascular age-related macular degeneration (NV-AMD) patients and to assess the influence of the number of prior injections on this response. Methods: Fifteen NV-AMD patients were prospectively recruited and grouped according to the dosage of ranibizumab previously received. Group 1 NV-AMD patients (n = 7) had previously received 1.50 mg or less, and group 2 patients (n = 8) had received more than 1.50 mg in the study eye. A group of 12 non-NV AMD patients were also recruited for control comparison. Vessel diameter, centreline blood velocity and blood flow were assessed with the Canon Laser Blood Flowmeter immediately prior to an injection and at a mean follow-up of 37.7 and 36.7 days for group 1 and group 2 patients, respectively. Results: The NV-AMD patients as a whole and the group 1 cohort had a significantly greater arteriolar diameter at baseline than the non-NV AMD patients. There was a significant reduction in arteriolar diameter, velocity and blood flow in group 1 but not in group 2 NV-AMD patients at follow-up. There was only an insignificant decrease in measured parameters of the retinal venules. At follow-up, there was no difference in the diameter, velocity or flow between AMD patients. Conclusion: Intravitreal ranibizumab treatment for NV-AMD induces a reduction in arteriolar diameter, velocity, and blood flow in patients who have received <1.50 mg of ranibizumab. © 2011 Acta Ophthalmologica Scandinavica Foundation.-
dc.languageeng-
dc.relation.ispartofActa Ophthalmologica-
dc.subjectage-related macular degeneration-
dc.titleRetinal blood flow in response to an intravitreal injection of ranibizumab for neovascular age-related macular degeneration-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1755-3768.2011.02209.x-
dc.identifier.pmid21801339-
dc.identifier.scopuseid_2-s2.0-84856551676-
dc.identifier.volume90-
dc.identifier.issue1-
dc.identifier.spagenull-
dc.identifier.epagenull-
dc.identifier.eissn1755-3768-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats